|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2008-11-3
|
|
pubmed:abstractText |
Cetuximab has demonstrated synergy with taxanes in preclinical models; as well as single agent activity. We assessed the activity of cetuximab with carboplatin and paclitaxel given on a 4-week schedule, in advanced, chemo-naive non-small cell lung cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1556-1380
|
|
pubmed:author |
pubmed-author:BorghaeiHosseinH,
pubmed-author:CohenRogerR,
pubmed-author:LangerCorey JCJ,
pubmed-author:LitwinSamuelS,
pubmed-author:MillensonMichaelM,
pubmed-author:MintzerDavidD,
pubmed-author:RovitoMarcM,
pubmed-author:RuthKaren JKJ,
pubmed-author:SeldomridgeJudie SylvesterJS,
pubmed-author:TreatJosephJ,
pubmed-author:TuttleHollyH
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1286-92
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18978564-Adenocarcinoma,
pubmed-meshheading:18978564-Adenocarcinoma, Bronchiolo-Alveolar,
pubmed-meshheading:18978564-Aged,
pubmed-meshheading:18978564-Antibodies, Monoclonal,
pubmed-meshheading:18978564-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18978564-Carboplatin,
pubmed-meshheading:18978564-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:18978564-Carcinoma, Squamous Cell,
pubmed-meshheading:18978564-Female,
pubmed-meshheading:18978564-Humans,
pubmed-meshheading:18978564-Lung Neoplasms,
pubmed-meshheading:18978564-Male,
pubmed-meshheading:18978564-Maximum Tolerated Dose,
pubmed-meshheading:18978564-Middle Aged,
pubmed-meshheading:18978564-Neoplasm Staging,
pubmed-meshheading:18978564-Paclitaxel,
pubmed-meshheading:18978564-Prognosis,
pubmed-meshheading:18978564-Receptor, Epidermal Growth Factor,
pubmed-meshheading:18978564-Survival Rate
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.
|
|
pubmed:affiliation |
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA. hossein.borghaei@fccc.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
